How to access

This ESMO Webinar Series is available to all ESMO Members.

You will need to log in with your ESMO membership and click on the registration button. Access to the webinar will be open 30 min before the session starts.

Become an ESMO Member

Apply for an ESMO membership to register for this ESMO Webinar and enjoy all the benefits exclusive for members

Live viewers of the webinar will be awarded a certificate of attendance and 1 ESMO-MORA category 1 point

Programme

22 May 2024

5 min

Welcome and introduction

Evandro de Azambuja

15 min

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study

Benjamin Besse

15 min

Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer

Patrizia Giannatempo

15 min

Ribociclib plus endocrine therapy in early breast cancer

Valentina Guarneri

10 min

Live Q&A and Discussion

All speakers

Chair’s welcome

It is with great pleasure that I invite you to participate in the first ESMO Virtual Journal Club Webinar which will focus on three newly published studies, with an aim to enhance understanding and application of the latest research in the field.

In this webinar we will be discussing and evaluating notable recent publications on the topics of non-small cell lung cancer, urothelial cancer and lastly, breast cancer

I am delighted to announce the distinguished speakers who will join me in this webinar, and I encourage and invite you to register and join us all in this new ESMO activity.

Dr. Evandro de Azambuja
Jules Bordet Institute, Brussels, Belgium

Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35(1):77-90. doi:10.1016/j.annonc.2023.10.117

Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875-888. doi:10.1056/NEJMoa2312117

Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488

Speakers

Evandro de Azambuja
Chair

Jules Bordet Institute - Brussels
Benjamin Besse
Speaker

Gustave Roussy Institute and Paris-Saclay University
Patrizia Giannatempo
Speaker

Instituto Nazionale dei Tumori
Valentina Guarneri
Speaker

Istituto Oncologico Veneto
Padua

Learning objectives

To discuss and critically evaluate notable recent publications.
To enhance the understanding and application of the latest research in the field.
To assess the study’s robustness, its significance to oncology practice, limitations, and its place within existing research.
To identify and highlight any unclear aspects or unmet needs.

Programme

Chair’s welcome

Speakers

Learning objectives

Meeting resources

Speakers

You may also be interested in...